Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/20/2005WO2005097618A2 Low dose therapy for treating viral infections
10/20/2005WO2005097261A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005WO2005097227A1 Biocompatible polyacrylate compositions for medical applications
10/20/2005WO2005097222A1 Process and systems for biocompatible surfaces
10/20/2005WO2005097211A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005WO2005097204A1 Preventives/remedies for cancer
10/20/2005WO2005097196A2 Pharmaceutical preparation containing drospirenone for application to the skin
10/20/2005WO2005097195A2 Methods of reducing aggregation of il-1ra
10/20/2005WO2005097193A2 Sequential sprm/progestin treatment
10/20/2005WO2005097192A2 Active substance combination of a carbinol compound and an opioid
10/20/2005WO2005097191A2 COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
10/20/2005WO2005097189A1 Carcinoma cell-specific apoptosis inducing agent targeting gene relevant to chromosome stabilization
10/20/2005WO2005097187A2 Methods of preventing uvb-induced skin damage
10/20/2005WO2005097162A2 Steroid sparing agents and their use
10/20/2005WO2005097161A2 Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury
10/20/2005WO2005097151A1 Antioxidant composition and products containing the same
10/20/2005WO2005097144A1 Composition for cleaning intestinal canal
10/20/2005WO2005097142A1 Biologically active compounds with anti-angiogenic properties
10/20/2005WO2005097141A2 Estrogen receptor modulators
10/20/2005WO2005097140A2 Selective antagonists of a2a adenosine receptors
10/20/2005WO2005097139A1 Method and composition for treatment of skin conditions
10/20/2005WO2005097138A2 Combinations comprising oxcarbazepine to treat affective disorders
10/20/2005WO2005097137A2 Advanced quinazoline based protein kinase inhibitors
10/20/2005WO2005097136A1 Biaryl substituted pyrazinones as sodium channel blockers
10/20/2005WO2005097135A2 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
10/20/2005WO2005097134A2 Quinazoline based protein kinase inhibitors
10/20/2005WO2005097133A1 Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
10/20/2005WO2005097132A2 Methods of treatment using eszopiclone
10/20/2005WO2005097131A2 Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
10/20/2005WO2005097130A1 New compositions and methods for maintaining eyelid hygiene
10/20/2005WO2005097129A2 6-azaindole compound
10/20/2005WO2005097128A1 1,4-bis-n-oxide azaanthracenediones and the use thereof
10/20/2005WO2005097127A2 Method of treating men with metabolic and anthropometric disorders
10/20/2005WO2005097126A1 Compounds for treating proliferative processes
10/20/2005WO2005097125A2 Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
10/20/2005WO2005097124A1 Liquid dosage formulations of donepezil
10/20/2005WO2005097123A2 Pyridyl-substituted porphyrin compounds and methods of use thereof
10/20/2005WO2005097122A2 Method of treating schizophrenia and/or glucoregulatory abnormalities
10/20/2005WO2005097121A1 Angiogenesis-affecting compounds and methods of use thereof
10/20/2005WO2005097120A1 Compositions with reduced hepatotoxicity
10/20/2005WO2005097119A2 Pten inhibitors
10/20/2005WO2005097118A1 Aldosterone receptor antagonists
10/20/2005WO2005097117A1 Thiadiazolidinones as gsk-3 inhibitors
10/20/2005WO2005097116A1 Composition comprising a jnk inhibitor and cyclosporin
10/20/2005WO2005097115A1 Use of repinotan for inhibition of opiate/opioid-induced respiratory depression
10/20/2005WO2005097114A2 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
10/20/2005WO2005097113A2 5-ht2b receptor antagonists
10/20/2005WO2005097112A2 Ion channel modulators
10/20/2005WO2005097111A2 Treatment of tremor with histamine h3 inverse agonists or histamine h3 antagonists
10/20/2005WO2005097110A1 Monotherapy for the modulation of intraocular pressure with cyclooxygenase-2 selective inhibitors
10/20/2005WO2005097109A1 Methods for achieving a protective ace2 expression level
10/20/2005WO2005097108A1 Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
10/20/2005WO2005097107A2 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005WO2005097106A1 Purifications of ellagitannins
10/20/2005WO2005097105A1 Injectable composition for the treatment of cancers
10/20/2005WO2005097104A1 SOLID PHARMACEUTICAL PREPARATION CONTAINING DIBENZ[b,e]OXEPINE DERIVATIVE
10/20/2005WO2005097103A2 Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
10/20/2005WO2005097102A2 Method to treat chronic heart failure and/or elevated cholesterol levels
10/20/2005WO2005097101A1 Sleep-improving composition
10/20/2005WO2005097100A2 Antibacterial agents
10/20/2005WO2005097099A1 Active substance combination comprising a carbinol combined to at least an nsaid
10/20/2005WO2005097098A2 Use of ppr delta agonists for treating demyelinating diseases
10/20/2005WO2005097097A1 Agent for controlling cholesterol homeostasis-associated gene transcription activity mediated by fxr activation
10/20/2005WO2005097096A1 A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
10/20/2005WO2005097095A1 (r,r)-formoterol in combination with other pharmacological agents
10/20/2005WO2005097094A1 Antimicrobial compositions and methods for their use
10/20/2005WO2005097093A1 Sleep inducing compounds and methods relating thereto
10/20/2005WO2005097092A1 Compound with vitamin k activity, particularly as additive for feeds, and preparation of the compound
10/20/2005WO2005097091A1 Composition comprising reduced-form coenzyme q10 and carotenoid compound
10/20/2005WO2005097090A2 AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF
10/20/2005WO2005097089A2 Derivatives of leinamycin for use as anticancer agents
10/20/2005WO2005097088A2 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
10/20/2005WO2005097087A2 Merged ion channel modulating compounds and uses thereof
10/20/2005WO2005097086A2 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
10/20/2005WO2005097085A1 Nutrient system for individualized responsive dosing regimens
10/20/2005WO2005097084A2 Calcium salts for the treatment of psoriasis, dermatitis and dandruff
10/20/2005WO2005097081A1 Ion binding polymers and uses thereof
10/20/2005WO2005097079A2 Controlled release dosage for gaba receptor agonist
10/20/2005WO2005097077A2 Spray dried pharmaceutical compositions
10/20/2005WO2005097076A2 Low dose pharmaceutical products
10/20/2005WO2005097072A1 Ion binding compositions
10/20/2005WO2005097068A1 Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
10/20/2005WO2005097062A1 deferasirox DISPERSIBLE TABLETS
10/20/2005WO2005097058A2 Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones
10/20/2005WO2005096840A1 Kiwifruit extracts and extraction methods
10/20/2005WO2005096836A1 Sinapic acid supplementation
10/20/2005WO2005096831A1 Fortified confectionery products
10/20/2005WO2005096784A2 Benzotriazine inhibitors of kinases
10/20/2005WO2005096734A2 Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
10/20/2005WO2005096717A2 Agent exhibiting hepatoprotective properties
10/20/2005WO2005096704A2 Cholesterol lowering composition
10/20/2005WO2005096692A2 Crystalline forms of mizolastine, production methods thereof and pharmaceutical compositions containing same
10/20/2005WO2005084713A3 Enzyme-prodrug therapy for prosthetic joint repair
10/20/2005WO2005084205A3 Diamino thiazoloindan derivatives and their use
10/20/2005WO2005083083A3 Materials and methods for treatment of allergic disease
10/20/2005WO2005075484A3 Chemokine ccr5 receptor modulators
10/20/2005WO2005075078A3 Method for the production of monodispersed pearl polymers containing acrylic
10/20/2005WO2005074887A3 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof
10/20/2005WO2005073237A3 Polymorphic forms of a gabaa agonist
10/20/2005WO2005073214A3 Novel inhibitors of chymase
1 ... 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 ... 7860